

## ANTICONVULSANTS

---

### Products Affected

#### Step 2:

- APTIOM TABLET 200 MG ORAL
- APTIOM TABLET 400 MG ORAL
- APTIOM TABLET 600 MG ORAL
- APTIOM TABLET 800 MG ORAL
- DILANTIN CAPSULE 30 MG ORAL
- FYCOMPA SUSPENSION 0.5 MG/ML ORAL
- FYCOMPA TABLET 10 MG ORAL
- FYCOMPA TABLET 12 MG ORAL
- FYCOMPA TABLET 2 MG ORAL
- FYCOMPA TABLET 4 MG ORAL
- FYCOMPA TABLET 6 MG ORAL
- FYCOMPA TABLET 8 MG ORAL
- MOTPOLY XR CAPSULE EXTENDED RELEASE 24 HOUR 100 MG ORAL
- MOTPOLY XR CAPSULE EXTENDED RELEASE 24 HOUR 150 MG ORAL
- MOTPOLY XR CAPSULE EXTENDED RELEASE 24 HOUR 200 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 1000 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 750 MG ORAL
- SYMPAZAN FILM 10 MG ORAL
- SYMPAZAN FILM 20 MG ORAL
- SYMPAZAN FILM 5 MG ORAL
- VALTOCO 10 MG DOSE LIQUID 10 MG/0.1ML NASAL
- VALTOCO 15 MG DOSE LIQUID THERAPY PACK 7.5 MG/0.1ML NASAL
- VALTOCO 20 MG DOSE LIQUID THERAPY PACK 10 MG/0.1ML NASAL
- VALTOCO 5 MG DOSE LIQUID 5 MG/0.1ML NASAL

### Details

---

Criteria
Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of a generic formulary anticonvulsant in the past 365 days. Otherwise, a step therapy exception request will be required indicating: (1) history of inadequate treatment response with a generic formulary anticonvulsant, (2) history of adverse event with a generic formulary anticonvulsant, or (3) generic formulary anticonvulsants are contraindicated.

---

**Sonder Health Plans Diabetes Wellness (HMO C-SNP) and Heart Healthy (HMO C-SNP)  
2024 Step Therapy (ST) Criteria**

## **ANTIDEPRESSANTS**

---

### **Products Affected**

#### **Step 2:**

- AUVELITY TABLET EXTENDED RELEASE 45-105 MG ORAL
- EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL
- MARPLAN TABLET 10 MG ORAL
- TRINTELLIX TABLET 10 MG ORAL
- TRINTELLIX TABLET 20 MG ORAL
- TRINTELLIX TABLET 5 MG ORAL

### **Details**

---

<b>Criteria</b>	Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of any generic formulary antidepressant in the past 365 days. Otherwise, a step therapy exception request will be required indicating: (1) history of inadequate treatment response with a generic formulary antidepressant, (2) history of adverse event with a generic formulary antidepressant, or (3) generic formulary antidepressants are contraindicated.
-----------------	--

---

Formulary ID: 24458 version 18  
Last Updated: 11/24/2024  
Effective: 12/01/2024

**Sonder Health Plans Diabetes Wellness (HMO C-SNP) and Heart Healthy (HMO C-SNP)  
2024 Step Therapy (ST) Criteria**

## ATYPICALS

---

### Products Affected

#### Step 2:

- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- LYBALVI TABLET 10-10 MG ORAL
- LYBALVI TABLET 15-10 MG ORAL
- LYBALVI TABLET 20-10 MG ORAL
- LYBALVI TABLET 5-10 MG ORAL
- SECUADO PATCH 24 HOUR 3.8 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 5.7 MG/24HR TRANSDERMAL
- SECUADO PATCH 24 HOUR 7.6 MG/24HR TRANSDERMAL
- VERSACLOZ SUSPENSION 50 MG/ML ORAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- ZYPREXA RELPREVV SUSPENSION RECONSTITUTED 210 MG INTRAMUSCULAR

### Details

<b>Criteria</b>	Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of 2 generic formulary agents in the past 365 days. Otherwise, a step therapy exception request will be required indicating: (1) diagnosis that is not covered by 2 generic formulary agents, (2) history of inadequate treatment response with 2 generic formulary agents, (3) history of adverse event with 2 generic formulary agents, or (4) 2 generic formulary agents are contraindicated.
-----------------	--

Formulary ID: 24458 version 18  
 Last Updated: 11/24/2024  
 Effective: 12/01/2024

**Sonder Health Plans Diabetes Wellness (HMO C-SNP) and Heart Healthy (HMO C-SNP)  
2024 Step Therapy (ST) Criteria**

## **RYTARY**

---

### **Products Affected**

#### **Step 2:**

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

### **Details**

---

<b>Criteria</b>	
	Claim will pay automatically if enrollee has a paid claim for at least a 1 day supply of generic Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone in the past 365 days. Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone, (2) history of adverse event with Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone, or (3) Carbidopa, Carbidopa/Levodopa, or Carbidopa/Levodopa/Entacapone is contraindicated.

---

Formulary ID: 24458 version 18  
Last Updated: 11/24/2024  
Effective: 12/01/2024

**Sonder Health Plans Diabetes Wellness (HMO C-SNP) and Heart Healthy (HMO C-SNP)  
2024 Step Therapy (ST) Criteria**

**Index**

**A**

APTIOM TABLET 200 MG ORAL..... 1  
 APTIOM TABLET 400 MG ORAL..... 1  
 APTIOM TABLET 600 MG ORAL..... 1  
 APTIOM TABLET 800 MG ORAL..... 1  
 AUVELITY TABLET EXTENDED  
 RELEASE 45-105 MG ORAL ..... 2

**D**

DILANTIN CAPSULE 30 MG ORAL ..... 1

**E**

EMSAM PATCH 24 HOUR 12 MG/24HR  
 TRANSDERMAL..... 2  
 EMSAM PATCH 24 HOUR 6 MG/24HR  
 TRANSDERMAL..... 2  
 EMSAM PATCH 24 HOUR 9 MG/24HR  
 TRANSDERMAL..... 2

**F**

FANAPT TABLET 1 MG ORAL ..... 3  
 FANAPT TABLET 10 MG ORAL ..... 3  
 FANAPT TABLET 12 MG ORAL ..... 3  
 FANAPT TABLET 2 MG ORAL ..... 3  
 FANAPT TABLET 4 MG ORAL ..... 3  
 FANAPT TABLET 6 MG ORAL ..... 3  
 FANAPT TABLET 8 MG ORAL ..... 3  
 FANAPT TITRATION PACK TABLET 1  
 & 2 & 4 & 6 MG ORAL..... 3  
 FYCOMPA SUSPENSION 0.5 MG/ML  
 ORAL..... 1  
 FYCOMPA TABLET 10 MG ORAL..... 1  
 FYCOMPA TABLET 12 MG ORAL..... 1  
 FYCOMPA TABLET 2 MG ORAL..... 1  
 FYCOMPA TABLET 4 MG ORAL..... 1  
 FYCOMPA TABLET 6 MG ORAL..... 1  
 FYCOMPA TABLET 8 MG ORAL..... 1

**L**

LYBALVI TABLET 10-10 MG ORAL ..... 3  
 LYBALVI TABLET 15-10 MG ORAL ..... 3  
 LYBALVI TABLET 20-10 MG ORAL ..... 3  
 LYBALVI TABLET 5-10 MG ORAL ..... 3

**M**

MARPLAN TABLET 10 MG ORAL ..... 2

MOTPOLY XR CAPSULE EXTENDED  
 RELEASE 24 HOUR 100 MG ORAL ... 1  
 MOTPOLY XR CAPSULE EXTENDED  
 RELEASE 24 HOUR 150 MG ORAL ... 1  
 MOTPOLY XR CAPSULE EXTENDED  
 RELEASE 24 HOUR 200 MG ORAL ... 1

**R**

RYTARY CAPSULE EXTENDED  
 RELEASE 23.75-95 MG ORAL ..... 4  
 RYTARY CAPSULE EXTENDED  
 RELEASE 36.25-145 MG ORAL ..... 4  
 RYTARY CAPSULE EXTENDED  
 RELEASE 48.75-195 MG ORAL ..... 4  
 RYTARY CAPSULE EXTENDED  
 RELEASE 61.25-245 MG ORAL ..... 4

**S**

SECUADO PATCH 24 HOUR 3.8  
 MG/24HR TRANSDERMAL ..... 3  
 SECUADO PATCH 24 HOUR 5.7  
 MG/24HR TRANSDERMAL ..... 3  
 SECUADO PATCH 24 HOUR 7.6  
 MG/24HR TRANSDERMAL ..... 3  
 SPRITAM TABLET DISINTEGRATING  
 SOLUBLE 1000 MG ORAL ..... 1  
 SPRITAM TABLET DISINTEGRATING  
 SOLUBLE 250 MG ORAL ..... 1  
 SPRITAM TABLET DISINTEGRATING  
 SOLUBLE 500 MG ORAL ..... 1  
 SPRITAM TABLET DISINTEGRATING  
 SOLUBLE 750 MG ORAL ..... 1  
 SYMPAZAN FILM 10 MG ORAL..... 1  
 SYMPAZAN FILM 20 MG ORAL..... 1  
 SYMPAZAN FILM 5 MG ORAL..... 1

**T**

TRINTELLIX TABLET 10 MG ORAL..... 2  
 TRINTELLIX TABLET 20 MG ORAL..... 2  
 TRINTELLIX TABLET 5 MG ORAL..... 2

**V**

VALTOCO 10 MG DOSE LIQUID 10  
 MG/0.1ML NASAL..... 1

Formulary ID: 24458 version 18  
 Last Updated: 11/24/2024  
 Effective: 12/01/2024

**Sonder Health Plans Diabetes Wellness (HMO C-SNP) and Heart Healthy (HMO C-SNP)  
2024 Step Therapy (ST) Criteria**

VALTOCO 15 MG DOSE LIQUID THERAPY PACK 7.5 MG/0.1ML NASAL .....	1	VRAYLAR CAPSULE 1.5 MG ORAL .....	3
VALTOCO 20 MG DOSE LIQUID THERAPY PACK 10 MG/0.1ML NASAL .....	1	VRAYLAR CAPSULE 3 MG ORAL .....	3
VALTOCO 5 MG DOSE LIQUID 5 MG/0.1ML NASAL.....	1	VRAYLAR CAPSULE 4.5 MG ORAL .....	3
VERSACLOZ SUSPENSION 50 MG/ML ORAL.....	3	VRAYLAR CAPSULE 6 MG ORAL .....	3
		<b>Z</b>	
		ZYPREXA RELPREVV SUSPENSION RECONSTITUTED 210 MG INTRAMUSCULAR .....	3

Formulary ID: 24458 version 18  
Last Updated: 11/24/2024  
Effective: 12/01/2024